Clinical trial
Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on…
NCT00332137 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00332137 |
|---|---|
| Title | Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects |
| Official title | Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Health |
| Intervention type | Drug |
| Interventions | Tolterodine |
| Enrollment | 36 |
| Start date | Sep 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jun 1, 2006 |
| Last update posted | Mar 23, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: